Regenxbio Series C

REGENXBIO is a clinical-stage biotechnology company focused on developing gene therapies using its proprietary NAV Technology Platform, which utilizes adeno-associated virus (AAV) vectors. The company aims to improve lives by delivering one-time treatments for rare and retinal diseases, as well as metabolic and neurodegenerative conditions. Their pipeline includes investigational therapies for Duchenne muscular dystrophy, MPS II, MPS I, and wet age-related macular degeneration.